Related Experiment Videos
[Gemcitabine in peritoneal mesothelioma: a case report]
A Amodio1, M Crecco, P Del Medico
1Istituto Regina Elena per lo Studio e la Cura dei Tumori, Roma, Italia.
La Clinica Terapeutica
|April 1, 1999
Summary
Gemcitabine chemotherapy led to significant tumor regression and symptom relief in a patient with malignant peritoneal mesothelioma. This rare cancer shows a positive response to gemcitabine, offering a new treatment avenue.
Area of Science:
- Oncology
- Medical Research
Background:
- Malignant peritoneal mesothelioma is a rare cancer with a poor prognosis.
- Standard chemotherapy regimens were ineffective for this patient.
Observation:
- A 57-year-old woman presented with extensive peritoneal masses and ascites.
- The patient's condition was refractory to multiple prior chemotherapeutic treatments.
Findings:
- Chemotherapy with gemcitabine resulted in a dramatic regression of the disease.
- Serum CA-125 levels decreased in correlation with tumor regression.
- The patient experienced symptomatic improvement and a 12-month duration of response.
Implications:
- Gemcitabine demonstrates activity in treating malignant peritoneal mesothelioma.
- Combining gemcitabine with cisplatin may improve treatment outcomes.
- Further research, including multicenter trials, is warranted to explore combination therapies.